1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
GeneLink, Inc.

GeneLink, Inc.

GNLKQ
GeneLink, Inc.US flagOther OTC
0.00
USD
- -
- -
10,601.00Market Cap
GeneLink, Inc.
GNLKQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
TTM
FRC
- -
- -
- -
- -
0.01
0.01
0.01
- -
- -
0.08
0.08
0.06
0.03
0.01
0.01
Revenue per Share
-0.09
-0.08
-0.06
-0.08
-0.05
-0.07
-0.03
-0.02
-0.03
-0.03
-0.02
-0.02
-0.02
-0.01
-0.01
Basic EPS, GAAP
-0.03
-0.03
-0.01
-0.05
-0.04
-0.04
-0.01
-0.01
-0.02
-0.02
-0.02
-0.01
-0.02
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.28
-0.31
-0.31
-0.33
-0.29
-0.29
-0.28
-0.28
-0.25
-0.17
-0.15
-0.14
-0.12
-0.12
-0.1
Book Value per Share
-0.04
-0.06
-0.01
-0.02
0.03
-0.01
-0.02
-0.02
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.01
Tangible Book Value per Share
10
12
15
18
24
31
36
39
48
83
112
135
181
214
258
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
6
9
8
5
2
2
Sales/Revenue/Turnover
-6,557.36
-1,952.17
-4,982.46
-1,698.06
-888.71
-694.14
-322.77
-450.19
-1,294.7
-35.02
-28.76
-30.65
-76.14
-159.33
-124.82
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
-1
-1
-1
-2
-1
-1
-2
-3
-3
-3
-4
-3
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-7,394.69
-2,400.18
-5,213.1
-2,318.48
-952.51
-694.14
-265.26
-332.81
-1,596.64
-40.82
-31.73
-33.61
-81.76
-142.86
-128.81
Profit Margin (%)
- -
-1
- -
- -
1
- -
- -
-1
- -
-1
- -
-1
- -
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
LT Debt
- -
-1
- -
- -
1
- -
-1
-1
- -
- -
-1
-1
-1
-3
-3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'13
Jun'13
Sep'13
ST Debt
- -
- -
- -
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
253
258
265
Market Capitalization
2
3
2

Working Capital

FRC

•

in mil. unless spec.
Mar'13
Jun'13
Sep'13
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-172.12%
-283.01%
79.7%
Free Cash Flow
30.49%
37.96%
-17.84%
Net Income, GAAP
22.17%
18.64%
-20.32%
Sales/Revenue/Turnover
652.58%
1,271.16%
-54.4%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
1
1
1
1
5
2012
1
1
- -
- -
2
2013
- -
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
- -
- -
- -
- -
-0.02
2012
- -
- -
- -
- -
-0.01
2013
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
Similar Companies
Puma Biotechnology, Inc. (PBYI)
Naturally Splendid Enterprises Ltd. (NSPDF)
Sirnaomics Ltd. (2257.HK)
Curative Biotechnology, Inc. (CUBT)
Reviva Pharmaceuticals Holdings, Inc. (RVPHW)
Zealand Pharma A/S (ZLDPF)
Business
GeneLink, Inc. (GNLKQ) supplies premium custom oligonucleotides and genetic research tools to universities, research institutes, pharmaceutical companies, and hospitals worldwide. The company offers custom DNA and RNA oligonucleotide synthesis up to 250 mers and 125 mers respectively, including ultra-modified oligos, 2'O-methyl, chimerics, siRNA, fluorescently labeled probes such as Molecular Beacons, TaqMan, and FRET; molecular biology products including linkers, adaptors, DNA purification and clean-up kits; gene detection systems and reagents for triple repeat disorders like Fragile X, Myotonic Dystrophy, and Huntington's Disease, as well as genotyping kits for Sry, X and Y chromosomes, sickle cell anemia, and cystic fibrosis; and additional genetic tools, reagents, gene assays, and non-radioactive detection systems. GeneLink operates from facilities in Westchester County, New York, with direct sales in the United States and a network of over 26 international distributors; founded in 1993 as Gene Link, Inc., it maintains a global customer base through personalized technical support and a focus on innovative, high-quality genetic products. The company remains in bankruptcy proceedings, with no major acquisitions, funding rounds, partnerships, or product launches reported in the last two years amid minimal revenue of $1.58 million and net losses; its stock trades at near-zero value on OTC Markets.